Shots:

• Biogen acquires Nightstar Therapeutics- in all stock transaction with its lead candidates NSR-REP1 & NSR-RPGR. Nightstar Therapeutics to receive $25.50 /share in cash for one day premium of 68% on closing of $15.16 making the total deal value $800M
• The focus of an acquisition is to strengthen Biogen’s portfolio in ophthalmology. Biogen expected to complete the acquisition in H2’19
• NST’s NSR-REP1 & NSR-RPGR are subretinal injections based on AVV vector used for the treatment of choroideremia (CHM) & X-linked retinitis pigmentosa (XLRP) respectively

Ref: Biogen | Image: Biogen